FDA Approves Biosimilar for Treatment of Multiple Inflammatory Diseases
Prescription Drugs
FDA Approves Biosimilar for Treatment of Multiple Inflammatory Diseases
2023-11-01 18:27:47
by Dan McCue

WASHINGTON — The Food and Drug Administration on Tuesday approved Wezlana, a biosimilar interchangeable with Stelara for the treatment of multiple inflammatory diseases. The agency said its approval of Wezlana, which is manufactured by Amgen, was based on a comprehensive... Read More

Straight From The Well
scroll top